OOIR: Observatory of International Research

Papers

(The TQCC of Bone Marrow Transplantation is 5. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-08-01 to 2025-08-01.)

Article	Citations
Immunogenicity of anti-SARS-CoV-2 Comirnaty vaccine in patients with lymphomas and myeloma who underwent autologous stem cell transplantation	255
Distinct clinico-biological features in AML patients with low allelic ratio FLT3-ITD: role of allogeneic stem cell transplantation in first remission	84
Adding 5-day decitabine to the conditioning regimen for haploidentical bone marrow transplantation in aplastic anaemia patients results in satisfactory clinical outcomes	67
The cellular composition and function of the bone marrow niche after allogeneic hematopoietic cell transplantation	66
Tandem hematopoietic stem cell transplant considerations in families with multiple siblings affected by DOCK8 deficiency	65
Effect of prophylactic or pre-emptive use of tyrosine kinase inhibitors post-Allo SCT in bcr-abl positive acute lymphoblastic leukemia: a subanalysis of GITMO ph-positive ALL study	62
When is a chimaera not a chimaera?	60
DNA methylation in circulating leukocytes is a novel biomarker in multiple myeloma	58
Autologous hematopoietic stem cell transplantation activity for lymphoma and multiple myeloma in China	57
Busulfan target exposure attainment in children undergoing allogeneic hematopoietic cell transplantation: a single day versus a multiday therapeutic drug monitoring regimen	56
Combinatorial inhibition of Tec kinases BTK and ITK is beneficial in ameliorating murine sclerodermatous chronic graft versus host disease	52
The 49th Annual Meeting of the European Society for Blood and Marrow Transplantation: Data Management Group – Poster Session (P725-P741)	47
The 49th Annual Meeting of the European Society for Blood and Marrow Transplantation: Van Bekkum Awards	45
Haploidentical-cord blood stem cell transplantation versus haploidentical stem cell transplantation for non-CR acute leukemia patients: a multicenter study	44
OBITUARY- Riccardo Saccardi (20th April 1956–19th February 2024)	42
Low-dose post-transplant cyclophosphamide with low-dose antithymocyte globulin for prevention of graft-versus-host disease in first complete remission undergoing 10/10 HLA-matched unrelated donor peri	42
Infection prevention practices among EBMT hematopoietic cell transplant centers: the EBMT Infectious Disease Working Party survey	39
Role of extracorporeal photopheresis in the management of acute and chronic graft versus disease: current status	38
Significant detrimental impact of pre-transplant mogamulizumab on the post-transplant outcome with a short interval between the last mogamulizumab and transplantation	33
Low Incidence of hepatic sinusoidal obstruction syndrome/veno-occlusive disease in adults undergoing allogenic stem cell transplantation with prophylactic ursodiol and low-dose heparin	32
Patient-generated strategies for strengthening adherence to multiple medication regimens after allogeneic stem cell transplantation: a qualitative study	32
Intermediate-dose TBI/fludarabine conditioning for allogeneic hematopoietic cell transplantation in patients with peripheral T-cell lymphoma	31
Novel factors to predict respiratory viral disease progression in allogeneic hematopoietic cell transplant recipients	30
CD28-costimulated CD19 CAR-T cells for pediatric mature non-Hodgkin B-cell lymphoma	30
Cytokine release syndrome: implications for transplant outcomes in haploidentical and HLA-matched HSCT using PTCy	30

Addition of ruxolitinib to standard graft-versus-host disease prophylaxis for allogeneic stem cell transplantation in aplastic anemia patients	29
T cell redirection as a new standard of care for relapsed multiple myeloma: impact on inpatient capacity, financial burden and infrastructural requirements in Germany	27
Prognostic impact of histopathologic features including histological grading and immunohistochemistry-positive cell counts in cytomegalovirus-gastrointestinal disease after allogeneic hematopoietic ce	26
Autologous stem cell boost improves persistent immune effector cell associated hematotoxicity following BCMA directed chimeric antigen receptor T (CAR T) cell therapy in multiple myeloma	25
The effect of posttransplant cyclophosphamide on ocular graft-versus-host disease	25
Prognostic significance of cytogenetic risk score in patients with secondary acute myeloid leukemia undergoing allogeneic stem cell transplantation from HLA-matched unrelated donors: a study from the	25
Artificial intelligence methods to estimate overall mortality and non-relapse mortality following allogeneic HCT in the modern era: an EBMT-TCWP study	23
Randomized phase 2 study of digital life coaching during transplantation for myeloma	23
Health-related quality of life in pediatric patients with β-thalassemia major after hematopoietic stem cell transplantation	23
Which is older, Medicine or Wine?	22
Haploidentical transplantation with post-transplant cyclophosphamide versus single cord blood transplantation in adults with relapsed/refractory non-Hodgkin lymphoma	22
Post-transplant cyclophosphamide compared to sirolimus/tacrolimus in reduced intensity conditioning transplants for patients with lymphoid malignancies	22
Cardiac complications associated with hematopoietic stem-cell transplantation	21
Eculizumab treatment in paediatric patients diagnosed with aHUS after haematopoietic stem cell transplantation: a HSCT-TMA case series from Japanese aHUS post-marketing surveillance	21
Busulfan plus cyclophosphamide vs. total body irradiation plus cyclophosphamide for allogeneic hematopoietic stem cell transplantation in patients with acute T lymphoblastic leukemia: a large-scale pr	21
Clostridium butyricum MIYAIRI 588 contributes to the maintenance of intestinal microbiota diversity early after haematopoietic cell transplantation	20
Effect of graft-versus-host disease on outcomes of HLA-haploidentical peripheral blood transplantation using post-transplant cyclophophamide	20
The 48th Annual Meeting of the European Society for Blood and Marrow Transplantation: Physicians - Oral Sessions (O009-O155)	19
Prior antibiotics exposure predicts early and prolonged CD19 CAR T-cell-related hematologic toxicity and prognosis in acute B-cell leukemia	19
Adaptive NK cells undergo a dynamic modulation in response to human cytomegalovirus and recruit T cells in in vitro migration assays	19
First allogeneic hematopoietic stem cell transplantation in RASGRP1 deficiency: long-term follow-up	19
Long-term survival with mixed chimerism in patients with AML and MDS transplanted after conditioning with targeted busulfan, fludarabine, and thymoglobulin	19
Individualized dose of anti-thymocyte globulin based on weight and pre-transplantation lymphocyte counts in pediatric patients: a single center experience	18
External validation and extended application of the transplant conditioning intensity score in acute myeloid leukemia	18
Outcome of haematopoietic cell transplantation in children with lysosomal acid lipase deficiency: a study on behalf of the EBMT Inborn Errors Working Party	18
Post-transplant cyclophosphamide, calcineurin inhibitor, and mycophenolate mofetil compared to anti-thymocyte globulin, calcineurin inhibitor, and methotrexate combinations as graft-versus-host diseas	18
Pre-transplant inflammation and its associations with acute GvHD and mortality in pediatric allogeneic hematopoietic stem cell transplantation patients	18
The 50th Annual Meeting of the European Society for Blood and Marrow Transplantation: Pharmacist Committee – Poster Session (P762-P770)	18
Limited utility of chimeric antigen receptor (CAR) T-cell retreatment: experience with a human anti-CD19 CAR	18
Fecal microbiota transplantation for the treatment of steroid-refractory, intestinal, graft-versus-host disease in a pediatric patient	18
High incidence of resistant breakthrough invasive fungal infections (IFD) in patients treated for acute gastrointestinal graft-versus-host disease (GI GVHD) following allogeneic haematopoietic cell tr	18
SARS-CoV-2-reactive antibody waning, booster effect and breakthrough SARS-CoV-2 infection in hematopoietic stem cell transplant and cell therapy recipients at one year after vaccination	17
The effect of center experience on allogeneic hematopoietic cell transplantation outcomes in acute myeloid leukemia	17
Impact of center volume on outcomes in allogeneic hematopoietic cell transplantation for children	17
Hematopoietic cell transplantation and cellular therapies in Europe 2022. CAR-T activity continues to grow; transplant activity has slowed: a report from the EBMT	17
High-dose chemotherapy with autologous haematopoietic stem cell transplantation in patients with isolated vitreoretinal lymphoma: a LOC network study	17
Efficacy of eculizumab in transplantation-associated thrombotic microangiopathy: results of the French nationwide study on behalf of the SFGM-TC and the CNR-MAT	17
Trends in allogeneic hematopoietic cell transplantation survival using population-based descriptive epidemiology method: analysis of national transplant registry data	17
Hypophosphatemia and pre-infusion thrombocytopenia as biomarkers for CRS and ICANS after CAR T therapy	17
An early post-transplant relapse prediction score in multiple myeloma: a large cohort study from the chronic malignancies working party of EBMT	17
GvHD prophylaxis with tacrolimus, sirolimus, and mycophenolate mofetil after reduced intensity conditioning hematopoietic stem cell allogeneic transplantation	16
Intensive chemotherapy followed by autologous stem cell transplantation in primary central nervous system lymphomas (PCNSLs). Therapeutic outcomes in real life—experience of the French Network	16
Efficacy and safety of belumosudil for treatment of cGVHD: multicenter retrospective analysis of the French cohort of the compassionate use program, on behalf of the French Society of Bone Marrow Tran	16
Donor lymphocyte infusion (DLI) post haploidentical stem cell transplantation (Haplo) with post-transplant cyclophosphamide (PTCy): crossing the human leukocyte antigen (HLA) barrier	16
Racial disparities in time to hematopoietic cell transplant among patients with hematologic malignancies at a large urban academic center	16
Incidence of cardiovascular disease in healthy Swedish peripheral blood stem cell donors – a nationwide study	15
Role and competencies of the EBMT clinical pharmacists and clinical pharmacologists: a pan-European survey	15
Life 2.0: a comprehensive cross-sectional profiling of long-term allogeneic hematopoietic cell transplantation survivors compared to a matched general population cohort	15
Are we there yet?	15
Allogeneic hematopoietic stem cell transplantation for adult acute myeloid leukemia patients with nucleoporin 98 (NUP98) gene rearrangements: a real-world study in China	15

The 50th Annual Meeting of the European Society for Blood and Marrow Transplantation: Pharmacist Committee – Oral Session (O155-O159)	15
Shorter long-term post-transplant life expectancy may be due to prior chemotherapy for the underlying disease: analysis of 3012 patients with acute myeloid leukemia enrolled on 9 consecutive ECOG-ACRI	15
Quantile regression for censored data in haematopoietic cell transplant research	15
Treatment outcome and efficacy of therapeutic plasma exchange for transplant-associated thrombotic microangiopathy in a large real-world cohort study	15
Molecular alterations monitoring in myelodysplastic patients receiving an allogeneic hematopoietic stem cell transplantation after a reduced-intensity conditioning regimen	15
Towards a more inclusive unrelated donor registry	15
Outcomes of patients undergoing allogeneic haematopoietic stem cell transplantation for congenital amegakaryocytic thrombocytopenia; a study on behalf of the PDWP of the EBMT	15
Return to school practices after hematopoietic cell transplantation: a survey of transplant centers in the United States	14
Autologous hematopoietic stem cell transplantation in severe, refractory stiff person syndrome: a case series	14
The 50th Annual Meeting of the European Society for Blood and Marrow Transplantation: Psychiatry and Psychology Group – Poster Session (P756-P761)	14
Tuberculosis after hematopoietic cell transplantation: retrospective study on behalf of the Infectious Diseases Working Party of the EBMT	14
Ruxolitinib for the treatment of acute and chronic graft-versus-host disease in children: a systematic review and individual patient data meta-analysis	14
Physical performance before and after hematopoietic stem cell transplantation in pediatric patients: a potential role for prehabilitation	14
Alemtuzumab treatment for steroid-refractory acute graft-versus-host disease leads to severe immunosuppression but not to relapse of malignant disease	14
Myeloablative conditioning with thiotepa-busulfan-fludarabine does not improve the outcome of patients transplanted with active leukemia: final results of the GITMO prospective trial GANDALF-01	14
Comparative study of treosulfan plus Fludarabine (FT14) with busulfan plus Fludarabine (FB4) for acute myeloid leukemia in first or second complete remission: An analysis from the European Society for	14
Safety and efficacy of brincidofovir for Adenovirus infection in children receiving allogeneic stem cell transplantation: an AIEOP retrospective analyses	14
The 49th Annual Meeting of the European Society for Blood and Marrow Transplantation: Psychiatry and Psychology Group – Poster Session (P709-P715)	14
CD34-selected stem cell boost as therapy for late graft rejection following allogeneic transplantation for sickle cell disease	14
Non-myeloablative allogeneic stem cell transplant with fludarabine and reduced dose cyclophosphamide in acute myeloid leukemia for older adults with comorbidities	14
Molecular measurable residual disease monitoring and transplant indications in NPM1 mutated acute myeloid leukemia	13
Progressive multifocal leukoencephalopathy after CAR-T cell therapy	13
Wine, blood and religion	13
Maximum-tolerated dose of lomustine used in combination with etoposide and cyclophosphamide in conditioning regimen for hematopoietic stem cell transplantation in lymphoma patients	13
Decision making on HSCT in patients with hemoglobinopathies; an EBMT Pediatric Diseases Working Party and Inborn Errors Working Party scenario-based survey on physicians’ perspectives	13
Allogeneic hematopoietic cell transplantation for myelodysplastic syndrome unclassifiable – a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMT	13
Allogeneic hematopoietic stem cell transplantation for adults with therapy-related acute myeloid leukaemia: a retrospective multicentre study on behalf of the SFGM-TC	13
Impact of CDC warning on co-prescribing of opioids and benzodiazepines in older allogeneic hematopoietic cell transplant recipients	13
Durable remission of refractory and advanced stage mycosis fungoides/sezary syndrome utilizing an “outpatient” alemtuzumab, fludarabine-based reduced intensity allogeneic hematopoietic cell transplant	13
Clofarabine and total body irradiation (TBI) as conditioning regimen for allogeneic stem cell transplantation in high-risk acute leukemia patients: a two-center retrospective cohort study	13
Outcomes of third allogeneic hematopoietic stem cell transplantation in relapsed/refractory acute leukemia after a second transplantation	13
Hematopoietic stem cell transplantation for pediatric patients with non-anaplastic peripheral T-cell lymphoma. An EBMT pediatric diseases working party study	13
Outcomes of allogeneic stem cell transplant in adult Philadelphia negative acute lymphoblastic leukemia patients treated with the pediatric-inspired GIMEMA 1913 protocol. A Campus ALL study	12
Chimerism analysis for clinicians: a review of the literature and worldwide practices	12
Physically “fit” for allogeneic stem cell transplant?	12
Venetoclax and azacitidine followed by allogeneic transplant results in excellent outcomes and may improve outcomes versus maintenance therapy among newly diagnosed AML patients older than 60	12
Lung transplantation for pulmonary graft versus host disease: experience from a referral organ transplantation center	12
Comparison of fludarabine/melphalan (FluMel) with fludarabine/melphalan/BCNU or thiotepa (FBM/FTM) in patients with AML in first complete remission undergoing allogeneic hematopoietic stem cell transp	12
A practical guide to therapeutic drug monitoring in busulfan: recommendations from the Pharmacist Committee of the European Society for Blood and Marrow Transplantation (EBMT)	12
Survival outcomes and risk factors of second allogeneic hematopoietic cell transplantation in non-remission status for acute myeloid leukemia	12
The improvement in overall survival from unrelated donor transplantation in Australia and New Zealand is driven by a reduction in non-relapse mortality: A study from the ABMTRR	12
The 49th Annual Meeting of the European Society for Blood and Marrow Transplantation: Lectures	12
Blood and marrow transplant within 4 weeks of SARS-CoV-2 infection is associated with increased risk of mortality: a National COVID Cohort Collaborative (N3C) Study	12
Relationship between morphologic remission with or without hematologic recovery and outcome after allogeneic hematopoietic cell transplantation in adult acute myeloid leukemia	12
Myeloablative conditioning regimens in adult patients with acute myeloid leukemia undergoing allogeneic hematopoietic stem cell transplantation in complete remission: a systematic review and network m	12
Impact of chronic graft-versus-host-disease on intensive care outcome in allogeneic hematopoietic stem cell recipients	12
Efficacy and safety of relmacabtagene autoleucel, an anti-CD19 chimeric antigen receptor T cell, in relapsed/refractory B-cell non-Hodgkin’s lymphoma: 2-year results of a phase 1 trial	12
A phase 1 dose-escalation study of low-dose lenalidomide maintenance post-allogeneic stem cell transplantation for high-risk acute myeloid leukaemia or myelodysplastic syndrome	12
Peripheral blood haploidentical hematopoietic cell transplantation for patients aged 70 years and over with acute myeloid leukemia or high-risk myelodysplastic syndrome	12
Rituximab added to conditioning regimen significantly improves erythroid engraftment in major incompatible ABO-group hematopoietic stem cell transplantation	11
Correction to: Idelalisib treatment prior to allogeneic stem cell transplantation for patients with chronic lymphocytic leukemia: a report from the EBMT chronic malignancies working party	11
Post-thaw CD34+ cell recovery likely degraded under extreme graft platelet concentrations	11
The 50th Annual Meeting of the European Society for Blood and Marrow Transplantation: Patient Advocacy – Oral Session (O164-O169)	11
Gifts, wine and blood	11
Isocitrate dehydrogenase (IDH) 1 and 2 mutations predict better outcome in patients with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation: a study of the ALWP of the EBM	11
Split dose ATG strategy prevents grade III-IV acute GVHD and is associated with immune surrogates of GVL	11
Can pre-transplant 18F-choline positron emission tomography predict relapse following autologous stem cell transplantation in primary central nervous system lymphoma?	11
Outcome of human umbilical cord blood stem cell transplantation (CBT) for acute myeloid leukemia in patients achieving first complete remission after one versus two induction courses: a study from the	11
The 48th Annual Meeting of the European Society for Blood and Marrow Transplantation: Welcome Address	11
The 50th Annual Meeting of the European Society for Blood and Marrow Transplantation: Physicians – Poster Session (P001-P755)	10
aGvHDtrackR and cGvHDtrackR: shiny applications for graft versus host disease management and clinical data collection	10
An Exploration of COVID-19 Impact and Vaccine Hesitancy in Parents of Pediatric Hematopoietic Stem Cell Transplant (HCT) Recipients	10
Bone marrow versus peripheral blood stem cells as the graft source for allogeneic transplantation from HLA-matched relative donors in adult T-cell leukemia/lymphoma: A nationwide retrospective study b	10
Comparing stem cell mobilization with chemotherapy and cytokine (G-CSF) versus cytokine alone in myeloma patients (MOCCCA): a randomized phase II, open-label, non-inferiority trial	10
Emapalumab for the Treatment of Immune-Mediated Graft Failure after HSCT	10
Late stenosis of the small intestine and colon, an atypical feature of chronic graft-versus-host disease. National retrospective study in French pediatric allograft centers	10
Placental expanded mesenchymal-like cells (PLX-R18) for poor graft function after hematopoietic cell transplantation: A phase I study	10
Association of FLT3-ITD and NPM1 mutations with outcomes of allogeneic hematopoietic cell transplantation in acute myeloid leukemia	10
Allogeneic hematopoietic cell transplantation for patients with AML aged 70 years or older in first remission. A study from the Acute Leukemia Working Party of the European Society for Blood and Marro	10
Reduced prefrontal cortex and sympathetic nervous system activity correlate with fatigue after aHSCT	10
Dual T cell depletion for graft versus host disease prevention in peripheral blood haploidentical hematopoietic cell transplantation for adults with hematological malignancies	10
Posaconazole versus fluconazole as primary antifungal prophylaxis for patients at high risk of invasive fungal infections receiving allogeneic hematopoietic stem cell transplantation	10
Safety analysis of patients who received ruxolitinib for steroid-refractory acute or chronic graft-versus-host disease in an expanded access program	10
Bloodstream infections in allogeneic haematopoietic cell recipients from the Swiss Transplant Cohort Study: trends of causative pathogens and resistance rates	9
Impact of antithymocyte globulin usage and risk stratification for posttransplant lymphoproliferative disorders in aplastic anemia patients after allogeneic hematopoietic cell transplantation	9
Comparison of allo-SCT versus consolidation chemotherapy as post-remission therapy in acute lymphoblastic leukaemia aged ≥55 years	9
Correction: Haploidentical hematopoietic stem cell transplantation for hematologic malignancies: a novel conditioning regimen with anti-T lymphocyte immunoglobulin instead of anti-thymocyte globulin f	9
Sexual function of adult long-term survivors and their partners after allogeneic hematopoietic cell transplantation in Europe (S-FAST): a study from the Transplant Complications Working Party and Nurs	9
Assessment of Cytomegalovirus DNA doubling time and virus-specific T-cell responses in the management of CMV infection in allogeneic hematopoietic stem cell transplant recipients undergoing Letermovir	9
Evaluation of pre-transplant risk assessments in allogeneic hematopoietic cell transplant	9

Allogeneic hematopoietic cell transplantation with sequential conditioning regimen in relapsed refractory acute myeloid leukemia	9
Anti-T-lymphocyte globulin (ATLG) compared to post-transplant cyclophosphamide as GvHD prophylaxis in ALL patients undergoing allogeneic stem cell transplantation	9
Severity and organ distribution of chronic graft-versus-host disease with posttransplant cyclophosphamide-based versus methotrexate/calcineurin inhibitor-based allogeneic hematopoietic cell transplant	9
Defining a lineage-specific chimerism threshold for the use of donor lymphocyte infusions in treating myeloid malignancies	9
No impact of CD34+ cell dose on outcome among children undergoing autologous hematopoietic stem cell transplant for high-risk neuroblastoma	9
Microdissection testicular sperm extraction after pediatric allogeneic hematopoietic stem cell transplantation: a case series	9
The 48th Annual Meeting of the European Society for Blood and Marrow Transplantation: Pharmacist Committee – Poster Session (P590-P600)	9
High-dose aciclovir in CMV infection prophylaxis after allogeneic HSCT: a single-center long-term experience	9
Prognostic impact of the conditioning intensity on outcomes after allogeneic transplantation for MDS with low blasts: a nationwide retrospective study by the adult MDS working group of the Japan Socie	9
CALR mutations possess unique prognostic relevance in myelofibrosis—before and after transplant	9
Poor outcome of CHOEP induction followed by gemcitabine/busulfan/melphalan high-dose therapy and stem cell rescue for patients with newly diagnosed peripheral T-cell lymphoma	9
Old age in patients and vines	9
Double alkylators based conditioning reduced the relapse rate after allogeneic peripheral blood stem cell transplantation in adult patients with myeloid malignancies: a single arm phase II study	9
Favorable outcomes following CD34-selected stem cell boost for poor graft function after allogeneic hematopoietic stem cell transplantation	9
Predicting the loss of hepatitis B surface antigen following haematopoietic stem cell transplantation in patients with chronic HBV infection	9
Allogeneic hematopoietic cell transplantation in patients with juvenile myelomonocytic leukemia in Korea: a report of the Korean Pediatric Hematology-Oncology Group	9
Impact of donor-derived CD34 + infused cell dose on outcomes of patients undergoing allo-HCT following reduced intensity regimen for myelofibrosis: a study from the Chronic Malignancies Working Party	9
Better pre-transplant treatment options for TP53-mutated MDS: cytoreductive or non-cytoreductive therapy?	9
Timing of achieving MRD negativity for B-ALL patients with IKZF1 alterations in CR1 may dictate transplant decision: Autologous versus Allogeneic HSCT	9
Cord blood is a suitable donor source of allogeneic hematopoietic cell transplantation for adult T-cell leukemia-lymphoma: a nationwide retrospective study	9
Multivariate modeling of eosinophil markers and other cellular immune parameters associated with the development of chronic graft-versus-host disease	9
Evaluation of risk for bronchiolitis obliterans syndrome after allogeneic hematopoietic cell transplantation with myeloablative conditioning regimens	9
Outcomes of toxoplasmosis after allogeneic hematopoietic stem cell transplantation and the role of antimicrobial prophylaxis	9
Successful use of defibrotide to treat allogeneic hematopoietic stem cell transplantation associated thrombotic microangiopathy in pediatric patients: report from Chinese single center	8
Efficacy of SARS-CoV-2 primary and booster vaccine doses in CAR-T recipients – targeting the target antigen	8
Out of specification Tisagenlecleucel is associated with outcomes comparable to standard of care product in relapsed or refractory diffuse large B-cell lymphoma	8
Influence of comorbidities on outcome in 1102 patients with an allogeneic hematopoietic stem cell transplantation	8
Risk factors and long-term outcomes for human herpesvirus 6 encephalitis in the early period after allogeneic stem cell transplantation	8
Exposure to antibiotics with anaerobic activity before respiratory viral infection is associated with respiratory disease progression after hematopoietic cell transplant	8
Efficacy of CD19 directed therapies in patients with relapsed or refractory large b-cell lymphoma relapsing after CD19 directed chimeric antigen receptor T-cell therapy	8
HLA-identical related hematopoietic stem cell transplantation in severe sickle cell disease: age is not a barrier to successful outcome	8
Prognostic factors in 448 newly diagnosed multiple myeloma receiving bortezomib-based induction: impact of ASCT, transplant refusal and high-risk MM	8
Efficacy of artesunate for treatment of cytomegalovirus reactivation post allogeneic haematopoietic stem cell transplants	8
Correction: The 49th Annual Meeting of the European Society for Blood and Marrow Transplantation: Pharmacist Committee—Poster Session (P716-P724)	8
CD14 positive cells accelerate hematopoietic stem cell engraftment	8
GVHD prophylaxis with post-transplant cyclophosphamide results in lower incidence of GVHD and allows faster immunosuppressive treatment reduction compared to antithymocyte globulin in 10/10 HLA-matche	8
Favorable outcomes and the association between dynamic transfusion dependence and IPSS-M in MDS-h and MDS-LB patients undergoing allo-HSCT	8
The impact of GVHD on outcomes after adult single cord blood transplantation in European and Japanese populations	8
The 49th Annual Meeting of the European Society for Blood and Marrow Transplantation: Organising committee	8
Von Willebrand factor as a potential predictive biomarker of early complications of endothelial origin after allogeneic hematopoietic stem cell transplantation	8
Prophylactic versus Preemptive modified donor lymphocyte infusion for high-risk acute leukemia after allogeneic hematopoietic stem cell transplantation: a multicenter retrospective study	8
CMV prophylaxis with letermovir significantly improves graft and relapse free survival following allogeneic stem cell transplantation	8
Association between human herpesvirus-6 encephalitis and antiviral prophylaxis after allogeneic hematopoietic stem cell transplantation in the letermovir era	8
Letermovir prophylaxis lowers the incidence of Non-CMV infections after allogeneic hematopoietic cell transplantation	8
Dynamics of recent thymic emigrants in pediatric recipients of allogeneic hematopoetic stem cell transplantation	8
Treosulfan plus fludarabine versus TEAM as conditioning treatment before autologous stem cell transplantation for B-cell Non-Hodgkin lymphoma	8
Gastrointestinal involvement refines prognosis in minnesota standard risk acute graft-vs.-host disease	8
Maintenance therapy after second autologous hematopoietic cell transplantation for multiple myeloma. A CIBMTR analysis	8
Hematopoietic stem cell transplantation activity in China 2019: a report from the Chinese Blood and Marrow Transplantation Registry Group	8
Hematopoietic cell transplantation and cell therapy activity landscape survey in the Kingdom of Saudi Arabia; a report from the Saudi Society of Blood and Marrow Transplantation (SSBMT)	8
Psychosocial correlates of failure to complete hematopoietic stem cell transplants in a diverse population	8
Smoking cessation among blood or marrow transplant Survivors: a BMTSS Report	8
Ofatumumab as part of reduced intensity conditioning in high risk B-cell lymphoma patients: final long-term analysis from a prospective multicenter Phase-II Trial	8
The effect of danger-associated molecular patterns on survival in acute graft versus host disease	8
Allogeneic haematopoietic cell transplantation for therapy-related myeloid neoplasms arising following treatment for lymphoma: a retrospective study on behalf of the Chronic Malignancies Working Party	8
Long term results of a prospective multicenter observational study on the use of anti-human T-lymphocyte immunoglobulin (ATLG) in unrelated donor transplantation (ATOS study)	8
A high hematopoietic cell transplantation comorbidity Index (HCT-CI) does not impair outcomes after non-myeloablative allogeneic stem cell transplantation in acute myeloid leukemia patients 60 years o	8
Incidence of breakthrough COVID-19 in patients with hematological disorders who received pre-exposure prophylaxis with tixagevimab-cilgavimab: a retrospective study in Japan	8
The impact of individual comorbidities in transplant recipients receiving post-transplant cyclophosphamide	8
Comparison of fludarabine–melphalan and fludarabine–treosulfan as conditioning prior to allogeneic hematopoietic cell transplantation—a registry study on behalf of the EBMT Acute Leukemia Working Part	8
Graft engineering: how long can you wait, how low can you go, and pandemic readiness	8
Are any specific respiratory viruses more severe than others in recipients of allogeneic stem cell transplantation? A focus on lower respiratory tract disease	8
Cancer incidence in healthy Swedish peripheral blood stem cell donors	7
Community health status and long-term outcomes in 1-year survivors of autologous and allogeneic hematopoietic cell transplantation	7
A clinical solution for tracking clonal evolution of acute myeloid leukemia after allogeneic transplantation using bulk next generation sequencing	7
Mafosfamide, a cyclophosphamide analog, causes a proinflammatory response and increased permeability on endothelial cells in vitro	7
Outcomes in newly diagnosed young or high-risk myeloma patients receiving tandem autologous/allogeneic transplant followed by bortezomib maintenance: a phase II study	7
Fludarabine/TBI 8 Gy versus fludarabine/treosulfan conditioning in patients with AML in first complete remission: a study from the Acute Leukemia Working Party of the EBMT	7
In the era of Bortezomib-based Induction, intensification of Melphalan-based conditioning with Bortezomib does not improve Survival Outcomes in newly diagnosed Multiple Myeloma: a study from the Chron	7
Real-world outcomes of tandem ASCT in newly diagnosed multiple myeloma patients with standard risk features: a single-center analysis	7
Impact of graft CD34+ cell counts on hematological recovery in patients receiving post-transplant cyclophosphamide prophylaxis	7
KRD vs. VRD as induction before autologous hematopoietic progenitor cell transplantation for high-risk multiple myeloma	7
An adapted European LeukemiaNet genetic risk stratification for acute myeloid leukemia patients undergoing allogeneic hematopoietic cell transplant. A CIBMTR analysis	7
Correction: Case-cohort design in hematopoietic cell transplant studies	7
Acute kidney injury in peripheral blood haploidentical hematopoietic stem cell transplantation: should attract enough attention	7
Controversies about immunoglobulin replacement therapy in HSCT recipients with hypogammaglobulinemia	7
Cytogenetic abnormalities predict survival after allogeneic hematopoietic stem cell transplantation for pediatric acute myeloid leukemia: a PDWP/EBMT study	7
Intrathecal chemotherapy as treatment for chimeric antigen receptor T cell (CAR T) therapy associated neurotoxicity	7
Modified umbilical cord-blood transplantation for pediatric patients with mucopolysaccharidosis	7
Correction: ECP versus ruxolitinib in steroid-refractory chronic GVHD – a retrospective study by the EBMT transplant complications working party	7
Treosulfan, thiotepa and fludarabine conditioning regimen prior to first allogeneic stem cell transplantation in acute myeloid leukemia and high-risk myelodysplastic syndromes: a single center experie	7
Correction: Significance of men’s health in long-term survivors of allogeneic stem cell transplantation	7
Correction: Cryopreservation of unrelated donor hematopoietic stem cells: the right answer for transplantations during the COVID-19 pandemic?	7
Hematopoietic cell transplantation and cellular therapies in Europe 2021. The second year of the SARS-CoV-2 pandemic. A Report from the EBMT Activity Survey	7
Venetoclax is safe and tolerable as post-transplant maintenance therapy for AML patients at high risk for relapse	7
Development and validation of an automated computational approach to grade immune effector cell-associated hematotoxicity	7
The 49th Annual Meeting of the European Society for Blood and Marrow Transplantation: Quality Management Group – Oral Session (O176)	7
Objective and subjective physical function in allogeneic hematopoietic stem cell transplant recipients	7
Machine learning-based prediction of G-CSF-induced hematopoietic stem cell mobilization outcomes in healthy volunteers	7
Haploidentical allogeneic stem cell transplantation with post-transplant cyclophosphamide and subsequent kidney transplant for patients with severe sickle cell disease with end-stage kidney disease (E	7
Correction to: No difference in survival after HLA mismatched versus HLA matched allogeneic stem cell transplantation in Ewing sarcoma patients with advanced disease	7
Allogeneic hematopoietic stem cell transplantation from unmanipulated haploidentical donor and unrelated cord blood for T-cell lymphoma: a retrospective study from the Société Francophone de Greffe de	7
The impact of cult behavior on haematopoietic cell transplant practices: believers and non-believers	7
Post-transplant cyclophosphamide at 80 mg/kg with low dose post-engraftment anti-thymocyte globulin in haploidentical transplantation with myeloablative conditioning	7
Herpes simplex virus reactivation among hematopoietic stem cell transplant recipients: re-evaluating acyclovir dosage	7